(1S,2R,5R,6S,7S,8R,9R,11R,13R,14R)-15-[2-[3-cyclopentyloxy-N-[(3,5-dichloropyridin-4-yl)methyl]-4-methoxyanilino]ethylsulfanyl]-8-[(2S,3S,4R,6R)-3-(dimethylamino)-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-2-ethyl-6-hydroxy-9-methoxy-1,5,7,9,11,13-hexamethyl-3,17-dioxabicyclo[12.3.0]heptadecane-4,12,16-trione | 1185160-95-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: (1S,2R,5R,6S,7S,8R,9R,11R,13R,14R)-15-[2-[3-cyclopentyloxy-N-[(3,5-dichloropyridin-4-yl)methyl]-4-methoxyanilino]ethylsulfanyl]-8-[(2S,3S,4R,6R)-3-(dimethylamino)-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-2-ethyl-6-hydroxy-9-methoxy-1,5,7,9,11,13-hexamethyl-3,17-dioxabicyclo[12.3.0]heptadecane-4,12,16-trione
• CAS: 1185160-95-5
• 化学式: C₅₆H₈₄Cl₂N₄O₁₂S
• 分子量: 1108.27
• InChiKey: SENYVBCYBUXMNQ-AJMQQOCFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.7
• 重原子数：
  75
• 可旋转键数：
  16
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  193
• 氢给体数：
  1
• 氢受体数：
  17

反应信息

• 作为产物：
  描述：

  [(2S,3S,4R,6R)-6-[[(1S,2R,5R,6S,7S,8R,9R,11R,13R,14R)-15-[2-[3-cyclopentyloxy-N-[(3,5-dichloropyridin-4-yl)methyl]-4-methoxyanilino]ethylsulfanyl]-8-[(2S,3S,4R,6R)-3-(dimethylamino)-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-2-ethyl-9-methoxy-1,5,7,9,11,13-hexamethyl-4,12,16-trioxo-3,17-dioxabicyclo[12.3.0]heptadecan-6-yl]oxy]-4-methoxy-2,4-dimethyloxan-3-yl] acetate 在 盐酸 、 水 、 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 生成 (1S,2R,5R,6S,7S,8R,9R,11R,13R,14R)-15-[2-[3-cyclopentyloxy-N-[(3,5-dichloropyridin-4-yl)methyl]-4-methoxyanilino]ethylsulfanyl]-8-[(2S,3S,4R,6R)-3-(dimethylamino)-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-2-ethyl-6-hydroxy-9-methoxy-1,5,7,9,11,13-hexamethyl-3,17-dioxabicyclo[12.3.0]heptadecane-4,12,16-trione
  参考文献：
  名称：

  [EN] NEW MACROLIDES AND THEIR USE
  [FR] NOUVEAUX MACROLIDES ET LEUR UTILISATION

  摘要：

  本发明涉及公式(I)的大环内酯化合物，以及所述化合物作为药物的应用，特别是用于治疗或预防炎性和过敏性疾病，包含所述化合物的药物组合物，以及它们的制备过程。本发明特别涉及主要通过抑制磷酸二酯酶4（PDE4）介导抗炎活性的大环内酯化合物，这使得它们可用于治疗和/或预防诸如慢性阻塞性肺病（COPD）、哮喘、类风湿性关节炎、特应性皮炎、炎症性肠病或增殖性疾病，例如癌症等炎性和过敏性疾病。

  公开号：

  WO2009106419A1

文献信息

• MACROLIDES AND THEIR USE
  申请人：Kellenberger Johannes Laurenz

  公开号：US20110053876A1

  公开（公告）日：2011-03-03

  The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with anti-inflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.
• US8410065B2
  申请人：——

  公开号：US8410065B2

  公开（公告）日：2013-04-02